Innovating Works

NeuroFerro

Financiado
Ferroptosis Inhibitors For Neurodegenerative Disorders
FERROptosis inhibitors for NEUROdegenerative disorders (NeuroFerro) will focus on the development of potent compounds with improved pharmacokinetic properties, including blood-brain barrier (BBB) permeability for future applicatio... FERROptosis inhibitors for NEUROdegenerative disorders (NeuroFerro) will focus on the development of potent compounds with improved pharmacokinetic properties, including blood-brain barrier (BBB) permeability for future application in the treatment of neurodegenerative disorders. Ferroptosis is non-apoptotic programmed cell death that has been linked to the pathophysiological processes of many diseases, including dementia, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Neurological disorders are one of the most significant causes of disability-adjusted life-years and death worldwide with very limited treatment available. Although ferroptosis inhibitors developed by Augustyns and Vanden Berghe (supervisors) are currently best in class compounds, they suffer from no or minor BBB permeability. Therefore the main aim of the project will be the design and synthesis of novel ferroptosis inhibitors with improved pharmacokinetic parameters and high blood-brain barrier permeability to target ferroptosis in neurodegenerative disorders. ver más
31/03/2025
UANTWERPEN
240K€
Duración del proyecto: 31 meses Fecha Inicio: 2022-08-12
Fecha Fin: 2025-03-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-08-12
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021
Cerrada hace 3 años
Presupuesto El presupuesto total del proyecto asciende a 240K€
Líder del proyecto
UNIVERSITEIT ANTWERPEN No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5